Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure...
Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia December 03, 2018 Achieved statistical significance on primary imaging-based endpoint, changes in markers of central pain processing, in 11 subjects...
HARPOON THERAPEUTICS ANNOUNCES APPOINTMENT OF NATALIE R. SACKS, M.D., AS CHIEF MEDICAL OFFICER South San Francisco, CA – October 3, 2018 – Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing a new class of T cell engaging therapeutics,...
UNUM THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR PRESENTATION AT THE FOURTH CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE – Complete Responses Observed in Three of Six Patients with relapsed or refractory CD20-positive B cell non-Hodgkin...
Aptinyx Initiates Phase 1 Study of NYX-458 Development in Parkinson’s Disease Cognitive Impairment Planned EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies...
Truveris Expands Audit Capabilities with Launch of TruAudit™ Solution allows clients to track PBM performance by implementing several new audits NEW YORK–(BUSINESS WIRE)–Truveris, Inc. today announced new audit capabilities geared towards further...
Recent Comments